Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARD | Q03181 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13808401 | 0.88 | L3MBTL1 (0.39) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL13808363 | 0.88 | BCHE (0.35) | PPARAPPARGPPARD | |
| SCHEMBL13882350 | 0.76 | HCRTR1 (0.37) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL13808391 | 0.76 | GAA (0.36) | CASRGAA | |
| SCHEMBL13808392 | 0.76 | GAA (0.33) | GAA | |
| SCHEMBL13817435 | 0.73 | TP53 (0.31) | PPARAPPARGPPARD | |
| SCHEMBL17355540 | 0.73 | FGFR2 (0.36) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL9425594 | 0.71 | SMN1; SMN2 (0.42) | L3MBTL1GAA | |
| SCHEMBL18079355 | 0.70 | L3MBTL1 (0.37) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL15581199 | 0.70 | CYP2D6 (0.37) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MLX, FOXM1, SFXN1 | CYP1A2 1995/4885CYP2D6 1772/4885CYP2C19 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.